A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Trial Profile

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
    • 19 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Nov 2017 According to a Celldex Therapeutics media release, were presented at the 9th World Congress of Melanoma in October 2017 by the National Cancer Institute (NCI)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top